Umberto Tebano

Dr. Umberto Tebano


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Francesco FioricaFrancesco Fiorica
Francesco Fiorica
UTUmberto Tebano
Umberto Tebano
MGMilena Gabbani
Milena Gabbani
Mariasole PerroneMariasole Perrone
Mariasole Perrone
SMSonia Missiroli
Sonia Missiroli
Carlotta GiorgiCarlotta Giorgi
Carlotta Giorgi
Background: Immune checkpoint inhibitors (ICI) plus radiotherapy (RT) have been suggested as an emerging combination in non-small cell lung cancer (NSCLC) patients. However, little is known about the magnitude of its benefits and potential clinical predictors. Objective: To assess the effects of this combination on the increase in overall and progression-free survival. Data sources: The MEDLINE and CANCERLIT (1970–2020) electronic databases were searched, and the reference lists of included studies were manually searched. Study selection: Studies were included if they were comparative studies between combination ICI-RT and ICI or RT alone in advanced or metastatic NSCLC patients. Overall survival (OS) was analyzed according to the treatment strategy. Data extraction: Data on population, intervention, and outcomes were extracted from each study, in accordance with the intention-to-treat method, by two independent observers and combined using the DerSimonian method and Laird method. Results: Compared to ICI or RT alone, ICI-RT significantly increased the 1-year and 3-year OS RR by 0.75 (95% CI 0.64–0.88; p = 0.0003) and 0.85 (95% CI 0.78–0.93; p = 0.0006), respectively. Furthermore, there was a statistically significant benefit on 1- and 3-year progression-free survival (RR 0.73 (95% CI, 0.61–0.87; p = 0.0005) and RR 0.82 (95% CI 0.67–0.99; p = 0.04), respectively). Conclusions: In patients with advanced or metastatic NSCLC, combination ICI-RT increases 1- and 3-year OS and progression-free survival compared to ICI or RT alone.

8 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Mariasole PerroneMariasole Perrone
Mariasole Perrone
EREdoardo Raimondi
Edoardo Raimondi
MCMatilde Costa
Matilde Costa
GRGianluca Rasetto
Gianluca Rasetto
RRRoberto Rizzati
Roberto Rizzati
Francesco FioricaFrancesco Fiorica
Francesco Fiorica
Patient prognosis is a critical consideration in the treatment decision-making process. Conventionally, patient outcome is related to tumor characteristics, the cancer spread, and the patients’ conditions. However, unexplained differences in survival time are often observed, even among patients with similar clinical and molecular tumor traits. This study investigated how inflammatory radiomic features can correlate with evidence-based biological analyses to provide translated value in assessing clinical outcomes in patients with NSCLC. We analyzed a group of 15 patients with stage I NSCLC who showed extremely different OS outcomes despite apparently harboring the same tumor characteristics. We thus analyzed the inflammatory levels in their tumor microenvironment (TME) either biologically or radiologically, focusing our attention on the NLRP3 cancer-dependent inflammasome pathway. We determined an NLRP3-dependent peritumoral inflammatory status correlated with the outcome of NSCLC patients, with markedly increased OS in those patients with a low rate of NLRP3 activation. We consistently extracted specific radiomic signatures that perfectly discriminated patients’ inflammatory levels and, therefore, their clinical outcomes. We developed and validated a radiomic model unleashing quantitative inflammatory features from CT images with an excellent performance to predict the evolution pattern of NSCLC tumors for a personalized and accelerated patient management in a non-invasive way.

8 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Francesco FioricaFrancesco Fiorica
Francesco Fiorica
TSTeodoro Sava
Teodoro Sava
Jacopo GiulianiJacopo Giuliani
Jacopo Giuliani
UTUmberto Tebano
Umberto Tebano
GNGiuseppe Napoli
Giuseppe Napoli
MTMarcello Tucci
Marcello Tucci
Introduction: Metastasis-directed therapy (MDT) alone may be effective in preventing disease progression and positively affecting overall survival (OS) in oligometastatic prostate cancer (OMPC). Objective: We systematically reviewed the current literature to analyse the biological rationale for integrating MDT into treatment strategies for OMPC and investigate the current evidence on its role in OMPC. Evidence acquisition: MEDLINE/PUBMED and the EMBASE Database were systematically searched to identify eligible reports published up to January 2024. The proceedings of the European Society for Radiotherapy and Oncology, European Society of Medical Oncology, American Society for Radiation Oncology, American Society of Clinical Oncology, European Uro-Oncology Group, and American Urological Association annual meetings were analysed. Results: Eighteen studies published between 2014 and 2024 were selected for the analysis. The studies included 1058 patients treated with metastasis-directed radiotherapy. No statistically significant differences were found in terms of treatment-escalation-free survival between hormone-naïve patients treated with MDT alone and those treated with MDT and hormonal manipulation. By contrast, the combination treatment significantly increased both 2 year and 4 year disease-progression-free survival (DPFS) rates (p-values < 0.00001 and 0.006, respectively). In patients with castration-sensitive disease treated with MDT alone, the estimated 2 year and 4 year OS rates were 96.4% (95% confidence interval [CI], 92.9–100%) and 89.1% (95% CI, 82.3–96.5%), respectively. The estimated 2 year and 4 year overall survival rates in the combination treatment group were 86.1% (95% CI 79.2–93.7%) and 74.8% (95% CI 64.6.3–86.5%), respectively. Conclusions: MDT alone is associated with promising outcomes in OMPC and represents a valuable, valid, and often preferable strategy. Combined with ADT improves significantly disease-progression-free survival, but its impact on overall survival remains uncertain. Given these findings, the decision to incorporate ADT should be tailored to individual patient characteristics and clinical context. Future research should integrate biomarker-based approaches to optimise MDT use and select the best candidates for a multimodal approach.

8 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jacopo GiulianiJacopo Giuliani
Jacopo Giuliani
UTUmberto Tebano
Umberto Tebano
MMMarta Mandarà
Marta Mandarà
AFAntonella Franceschetto
Antonella Franceschetto
Carlotta GiorgiCarlotta Giorgi
Carlotta Giorgi
Francesco FioricaFrancesco Fiorica
Francesco Fiorica
Objectives: Despite optimal local control obtained with neoadjuvant chemoradiotherapy (CRT), data on overall survival (OS) and disease-free survival (DFS) of local advanced rectal cancer patients are still equivocal. This meta-analysis aimed to estimate the pathological complete response (pCR), regression rate, DFS, and OS probabilities of rectal cancer patients treated with a second chemotherapy drug added to fluoropyrimidine and long-term radiotherapy. Methods: Computerized bibliographic searches of MEDLINE, PUBMED, Web of Science and the Cochrane Central Register of Controlled Trials databases (1970–2023) were supplemented with hand searches of reference lists. Studies were included if they were randomised controlled trials (RCTs) comparing intensified chemotherapy with CRT to preoperative CRT and if they had patients with resectable, histologically proven rectal adenocarcinoma without metastases. Results: Eighteen RCTs (7695 patients) were analysed. Data on population, intervention, and outcomes were extracted from each RCT, following the intention-to-treat method, by three independent observers and combined using the DerSimonian and Laird methods. A chemotherapy with two drug and long-term radiotherapy CRT, compared to preoperative CRT (fluoropyrimidine and long-term radiotherapy), significantly increases the rate of pathological complete response (OR 1.37 (95% CI, 1.16–1.63) p = 0.0003) and the regression rate (OR 1.57 (95% CI, 1.16–2.14) p < 0.00001). Furthermore, it increases DFS (HR 0.87 (95% CI, 0.79 to 0.95) p = 0.002 and OS HR 0.84 (95% CI, 0.74 to 0.95) p = 0.007). The risk of severe adverse events (≥G3) is increased OR 1.96 (95% CI 1.35–2.85), p = 0.0005. Conclusions: In patients with resectable rectal cancer, intensified chemotherapy can reduce by 13% the risk of disease progression and by 16% the risk of death.

24 September 2026 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Francesco FioricaFrancesco Fiorica
Francesco Fiorica
MCMaria VIviana Candela
Maria VIviana Candela
Jacopo GiulianiJacopo Giuliani
Jacopo Giuliani
UTUmberto Tebano
Umberto Tebano
MMMarta Mandarà
Marta Mandarà
MTMarcello Tucci
Marcello Tucci
Background: Opioid-induced constipation (OIC) is a frequent and clinically relevant complication of long-term opioid therapy in both cancer and non-cancer populations, negatively affecting symptoms, treatment adherence, and health-related quality of life. Peripherally acting μ-opioid receptor antagonists (PAMORAs) represent a mechanism-based therapeutic approach targeting peripheral opioid effects while preserving analgesic activity. However, the overall value of PAMORAs, integrating clinical outcomes, patient-reported benefits, and health-economic implications, has not been comprehensively assessed. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing PAMORAs versus placebo in adults with OIC was performed. PubMed, Embase, Cochrane CENTRAL, and Web of Science were searched up to June 2025. Studies were stratified according to clinical setting (cancer versus non-cancer populations). The primary outcome was the change in mean weekly spontaneous bowel movements (SBMs). Secondary outcomes included constipation-related quality of life assessed by the Patient Assessment of Constipation–Quality of Life (PAC-QOL) questionnaire and health utility estimation through EQ-5D mapping. A two-step exploratory framework linking SBM improvement to PAC-QOL and subsequently to EQ-5D utilities was applied to extend the economic evaluation across the available evidence base. Results: Nineteen RCTs including 5565 patients (2785 PAMORA-treated and 2780 placebo-treated patients) were included. PAMORAs significantly increased weekly SBMs compared with placebo (mean difference [MD] 1.49; 95% CI 1.04–1.95; p < 0.0001). The treatment effect was highly consistent in non-cancer populations (MD 1.28; 95% CI 1.10–1.46; I2 = 0%) and larger but more heterogeneous in cancer populations (MD 2.67; 95% CI −0.001 to 5.35; I2 = 93.7%). In five trials reporting quality-of-life outcomes, PAMORAs were associated with a statistically significant improvement in PAC-QOL scores compared with placebo (MD −0.25; 95% CI −0.41 to −0.10); however, only one study demonstrated an improvement approaching a clinically meaningful threshold, limiting the certainty regarding the clinical relevance of the pooled effect. Mapping analyses provided an exploratory estimate of the relationship between bowel function, patient-reported quality of life, and EQ-5D utilities, allowing estimation of illustrative value-based treatment thresholds. Estimated acceptable monthly treatment costs ranged from approximately €25 to €101 depending on population and trial characteristics. Conclusions: PAMORAs consistently improve bowel function in patients with opioid-induced constipation across cancer and non-cancer settings. Available evidence also suggests an improvement in constipation-related quality of life, although the clinical relevance of this effect remains uncertain because of the limited number of studies and the lack of consistently clinically meaningful changes. The exploratory integration of clinical outcomes, patient-reported measures, and health-economic parameters provides a potential framework for personalized treatment evaluation, but the estimated economic thresholds should be interpreted cautiously and should not be considered direct estimates of cross-country cost-effectiveness.